Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients
with metastatic prostate cancer who have not received chemotherapy live longer when treated
with ipilimumab than those treated with a placebo